Reducing the Burden of Influenza-Associated Complications with Antiviral Therapy
- First Online:
- 195 Downloads
Influenza imposes an annual burden on individuals, society, and healthcare systems. This burden is increased by the development of complications that are often more severe than the primary infection. Here, we examine the main complications associated with influenza and review the effectiveness of antiviral therapy in reducing the incidence of such events.
Material and Methods:
The content of this review is taken from the study of the authors’ extensive collection of reference materials, examination of the bibliographical content of relevant papers, and the results of Medline searches.
The most commonly encountered complications in adults are sinusitis, pharyngitis, bronchitis, and, particularly in the elderly, bacterial pneumonia. Such complications may exacerbate pulmonary complaints. Children are particularly prone to post-influenza croup and otitis media. Complications involving the central nervous system, heart, or skeletal muscle also occur in influenza patients. Influenza-associated complications impose sizeable healthcare costs in terms of outpatient contacts, hospitalizations, and antibiotic use. Vaccination is the primary prevention strategy for influenza and its complications, but has limitations. Neuraminidase inhibitors have demonstrated efficacy in reducing the incidence of influenza-associated complications in populations with different ages and risks.
Influenza complications place a large burden on healthcare providers and society. Neuraminidase inhibitors can reduce the incidence of such complications, particularly in high-risk groups.
Unable to display preview. Download preview PDF.
- 1.Centers for Disease Control and Prevention (CDC): Key facts about seasonal influenza (flu). Revised 30 August 2006. Available online at: http://www.cdc.gov/flu/keyfacts.htm
- 6.Office of Technology Assessment. Washington, DC, 1984.Google Scholar
- 38.Centers for Disease Control and Prevention (CDC): Severe methicillin-resistent Staphylococcus aureus communityacquired pneumonia associated with influenza — Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325–329.Google Scholar
- 41.Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ, Advisory Committee on Immunization Practices (ACIP):, Centers for Disease Control and Prevention (CDC): Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 1–54.Google Scholar
- 43.Nicholson KG, Webster RG, Hay AJ: Textbook of influenza. Nicholson KG, Webster RG, Hay AJ (eds) Blackwell, London 1998.Google Scholar
- 47.Greaves K, Oxford JS, Price CP, Clarke GH, Crake T: The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults: measurement of cardiac troponins I and T in 152 patients with acute influenza infection. Arch Intern Med 2003; 163: 165–168.PubMedCrossRefGoogle Scholar
- 54.Centers for Disease Control and Prevention (CDC): Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 1–54.Google Scholar
- 59.Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337: 874–880.PubMedCrossRefGoogle Scholar
- 61.Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–1850.PubMedCrossRefGoogle Scholar
- 62.Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–1024.PubMedCrossRefGoogle Scholar
- 66.Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, Kashiwagi S: A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43: 439–444.PubMedCrossRefGoogle Scholar
- 76.Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M: Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007; CD002744.Google Scholar
- 79.Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, Wu XD, Gao H, Huo ZL, Zhu SH, Hu SL, Wang AX: A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 455–459.PubMedGoogle Scholar
- 84.Armstrong EP, Khan ZM, Perri AS, Perri LR: The cost effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary 2000; 35: 979–989.Google Scholar
- 86.Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, Fry-Smith A: Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1–87.Google Scholar
- 88.Brady B, McAuley L, Shukla VK: Economic evaluation of zanamivir for the treatment of influenza. Ottawa, ON. Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2001; Technology report no. 13.Google Scholar